Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Acquired chemoresistance to proteasome inhibitors is a major obstacle in managing multiple myeloma but key regulators and underlying mechanisms still remain to be explored. We find that high level of HP1γ is associated with low acetylation modification in the bortezomib-resistant myeloma cells using SILAC-based acetyl-proteomics assay, and higher HP1γ level is positively correlated with poorer outcomes in the clinic. Mechanistically, elevated HDAC1 in the bortezomib-resistant myeloma cells deacetylates HP1γ at lysine 5 and consequently alleviates the ubiquitin-mediated protein degradation, as well as the aberrant DNA repair capacity. HP1γ interacts with the MDC1 to induce DNA repair, and simultaneously the deacetylation modification and the interaction with MDC1 enhance the nuclear condensation of HP1γ protein and the chromatin accessibility of its target genes governing sensitivity to proteasome inhibitors, such as CD40, FOS and JUN. Thus, targeting HP1γ stability by using HDAC1 inhibitor re-sensitizes bortezomib-resistant myeloma cells to proteasome inhibitors treatment in vitro and in vivo. Our findings elucidate a previously unrecognized role of HP1γ in inducing drug resistance to proteasome inhibitors of myeloma cells and suggest that targeting HP1γ may be efficacious for overcoming drug resistance in refractory or relapsed multiple myeloma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A combined proteomics and acetylomics screen identified acetylation of K5 on heterochromatin protein 1 gamma (HP1γ) as one of the most significantly changed acetylation sites in BTZ-resistant MM cells, leading to the hypothesis that this site may confer BTZ resistance [116].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [116]
The cited source says what the claim attributes to it.
In the citing paper
“HDAC1/2 inhibitor, romidepsin, re-sensitized MM cells in tissue and mouse models to BTZ and when jointly administered with BTZ, significantly reduced tumor growth and increased apoptosis compared to BTZ treatment alone [116].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [116]
The cited source says what the claim attributes to it.
In the citing paper
“HDAC1/2 inhibitor, romidepsin, re-sensitized MM cells in tissue and mouse models to BTZ and when jointly administered with BTZ, significantly reduced tumor growth and increased apoptosis compared to BTZ treatment alone [116].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [116]
The cited source says what the claim attributes to it.
In the citing paper
“As such, BTZ-resistant cells use HDAC1-mediated stabilization of HP1γ to increase DNA repair, HP1γ’s ability to form nuclear condensates, and chromatin accessibility of genes implicated in DNA repair to confer drug resistance [116].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [116]
The cited source says what the claim attributes to it.
In the citing paper
“HP1γK5Ac destabilized the protein through an increase in ubiquitination (Figure 6C).”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Phase Separation: A New Phase in Cell Biology
Boeynaems, S., Alberti, S., Fawzi, N. L., Mittag, T., Polymenidou, M., Rousseau, F., Schymkowitz, J., Shorter, J., Wolozin, B., Van Den Bosch, L., et al. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.004 · Cited by 1,997
Liquid droplet formation by HP1α suggests a role for phase separation in heterochromatin
Larson, A. G., Elnatan, D., Keenen, M. M., Trnka, M. J., Johnston, J. B., Burlingame, A. L., Agard, D. A., Redding, S., & Narlikar, G. J. (2017) · Nature · doi:10.1038/nature22822 · Cited by 1,694
DNA double-strand break repair-pathway choice in somatic mammalian cells
Scully, R., Panday, A., Elango, R., & Willis, N. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0152-0 · Cited by 1,457
Ten principles of heterochromatin formation and function
Allshire, R. C., & Madhani, H. D. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.119 · Cited by 792
Phase separation of 53 BP 1 determines liquid‐like behavior of DNA repair compartments
Kilic, S., Lezaja, A., Gatti, M., Bianco, E., Michelena, J., Imhof, R., & Altmeyer, M. (2019) · The EMBO Journal · doi:10.15252/embj.2018101379 · Cited by 444
Ayrapetov, M. K., Gursoy-Yuzugullu, O., Xu, C., Xu, Y., & Price, B. D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403565111 · Cited by 391
Liquid-liquid phase separation in biology: mechanisms, physiological functions and human diseases
Zhang, H., Ji, X., Li, P., Liu, C., Lou, J., Wang, Z., Wen, W., Xiao, Y., Zhang, M., & Zhu, X. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1702-x · Cited by 351
The Heterochromatin Protein 1 family.
Lomberk, G. A., Wallrath, L. L., & Urrutia, R. A. (2006) · Genome biology · doi:10.1186/gb-2006-7-7-228 · Cited by 334
Acetylation of intrinsically disordered regions regulates phase separation
Saito, M., Hess, D., Eglinger, J., Fritsch, A. W., Kreysing, M., Weinert, B. T., Choudhary, C., & Matthias, P. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0180-7 · Cited by 300
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
Cited by
AI-powered therapeutic target discovery
Pun, F. W., Ozerov, I. V., & Zhavoronkov, A. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.010 · Cited by 341
Li, Y., Liu, Y., Yu, X., Xu, Y., Pan, X., Sun, Y. E., Wang, Y., Song, Y.-H., & Shen, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02013-w · Cited by 95
Self-citationPost-translational modifications in drug resistance
Miao, C., Huang, Y., Zhang, C., Wang, X., Wang, B., Zhou, X., Song, Y., Wu, P., Chen, Z., & Feng, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101173 · Cited by 81
Acetylation in pathogenesis: Revealing emerging mechanisms and therapeutic prospects
Jiang, N., Li, W., Jiang, S., Xie, M., & Liu, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115519 · Cited by 46
Subcellular localization as a driver of protein function
Sigaeva, A., Hutchings, C., Cesnik, A. J., Lilley, K. S., & Lundberg, E. K. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-026-00947-3 · Cited by 46
“By contrast, deacetylation of HP1γ promotes nuclear condensation, which results in drug resistance in myeloma 184 .”
Metadata
- Authors
- Li, X., Wang, S., Xie, Y., Jiang, H., Guo, J., Wang, Y., Peng, Z., Hu, M., Wang, M., Wang, J., Li, Q., Wang, Y., & Liu, Z.
- Affiliations
- Tianjin Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Corresponding author
- Liu, Zhiqiang
- ORCID
- Venue
- Nature Communications
- Published
- 2023-03-09
- Volume
- 14
- Issue
- 1
- Pages
- 1290-1290
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9998874
- OpenAlex
- W4323809200
- Cited by
- 27
- References
- 43
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 5 · 2023: 3
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82070221, 81870161, 81900215, 82270208)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- HP1γ, multiple myeloma, proteasome inhibitor resistance, bortezomib resistance, HDAC1, protein deacetylation, nuclear condensation, MDC1, DNA repair, chromatin accessibility, lysine acetylation, CD40, FOS, c-Jun
- MeSH terms
- Bortezomib, Antineoplastic Agents, Humans, Multiple Myeloma, Transcription Factors, Drug Resistance, Neoplasm, Cell Line, Tumor, Proteasome Endopeptidase Complex, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance. https://app.cochat.ai/papers/10.1038/s41467-023-37013-x
- The paper
- Li, X., Wang, S., Xie, Y., Jiang, H., Guo, J., Wang, Y., Peng, Z., Hu, M., Wang, M., Wang, J., Li, Q., Wang, Y., & Liu, Z. (2023). Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance. Nature Communications. https://doi.org/10.1038/s41467-023-37013-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.